[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-in-adolescence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-in-adolescence":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,49,79,106,133,168,196,219,243,279,304,329,362,395,417,441,461,487,498,528,547,574],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053248","neural-derived-plasma-exosomal-micrornas-as-promising-novel-biomarkers-for-suicidality-and-treatment-outcome-in-adolescents-100053248",false,"NCT05437588","Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents","Inclusion Criteria:\n\nAll participants:\n\n1. Physically healthy\n2. willing and able to provide informed consent (if under 18 also parent or guardian consent)\n\nMDD participants:\n\n1. A definite diagnosis of DSM-5\n2. a Children's Depression Rating Scale-Revised (CDRS-R) score \\>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \\>=4 rated over the last two weeks.\n\nSuicide attempt group:\n\n1\\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale.\n\nNon-psychiatric controls:\n\n1\\. No history of any major mental illness (excluding specific phobia) or substance use disorder.\n\nExclusion Criteria:\n\n* Exclusion criteria:\n\n  1. Pregnancy or lactation\n  2. post-partum state (being within 2 months of delivery or miscarriage);\n  3. homicide risk as determined by clinical interview\n  4. any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine\u002Fcaffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa.\n  5. recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months\n  6. use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.",true,"ALL","10 Years","24 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.",[27,28,29,30,31,32,33,34,35],"Major Depressive Disorder","Suicidal Ideas","Suicide, Attempted","MDD","Depression","Depression, Teen","Depression and Suicide","Depression in Adolescence","Suicide","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2022-10-01",{"date":44,"type":21},"2027-06-30",{"name":46,"class":47},"University of Alabama at Birmingham","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100564767","adolescent-psychiatry-inpatients-self-reported-parent-adolescent-communication-quality-and-treatment-outcome-100564767","NCT06633458","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality and Treatment Outcome","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality as a Predictor of Treatment Outcome","Inclusion Criteria:\n\n* Admission to inpatient care unit of the adolescent psychiatry at the University Medical Center Hamburg-Eppendorf.\n\nExclusion Criteria:\n\n* Severe symptom burden at admission\n* Lack of knowledge of the German language.","14 Years","17 Years",{"count":59,"type":21},60,"OBSERVATIONAL","The quality of parent-adolescent communication has been found to be associated with adolescent mental health. However, little is known about the association of parent-adolescent communication and adolescent mental health in the context of psychiatry inpatient treatment.\n\nThis study aims to find out whether self-reported parent-adolescent communication quality at the time of admission to psychiatry predicts the treatment outcome in terms of symptom reduction 6 months later in an adolescent inpatient sample. It also aims to track changes in adolescent self-reported communication quality in the course of inpatient treatment and afterwards (2, 4 and 6 months after admission) to see whether improvement predicts treatment outcome, with treatment outcome being defined as symptom reduction to baseline. As a secondary endpoint, it will be assessed whether a placement of the adolescent outside the family was considered during treatment and whether self-reported communication quality at the time of admission predicts the consideration of placement outside the family.",[63,34,64],"Mental Disorder in Adolescence","Anxiety",[66,67,68],"mental health","adolescence","communication","2026-06-28",{"date":71,"type":40},"2026-07-01",{"date":73,"type":40},"2024-07-08",{"date":75,"type":21},"2027-10-30",{"name":77,"class":47},"Universitätsklinikum Hamburg-Eppendorf",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100629528","teenthrive-2-treatments-for-improving-mood-in-teens-100629528","NCT07475845","Teenthrive 2: Treatments for Improving Mood in Teens","Set A Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 10 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;\n2. Be aged 12-18;\n3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);\n4. Be able to read and write in English;\n5. Provide consent\u002Fassent appropriate to age;\n6. Be able to attend group session times:\n7. Have access to a private space once per week that is suitable for synchronous intervention sessions.\n\nSet A Exclusion criteria: Adolescents will be excluded if they:\n\n1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;\n2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;\n3. Have severe depression (QIDS-A-CR score \\> = 16);\n4. Have moderate or high risk for suicide (Response of \"yes\" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).\n5. Have suicide ideation (Response of \"yes\" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)\n6. Are pregnant;\n7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT;\n8. Have had substantive changes in other psychiatric treatment in the previous 4 weeks (e.g., started a new depression medication; stopped or started attending psychotherapy).\n9. Have a sibling or other household member active in a study intervention (for this study) at the same time.\n\nSet B Eligibility criteria\n\nParticipants who are not eligible for Set A may be enrolled in Phase 2 Set B, such that they will be eligible to attend classes but their data will not be considered in our main analyses.\n\nSet B Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 6 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;\n2. Be aged 12-18;\n3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);\n4. Be able to read and write in English;\n5. Provide consent\u002Fassent appropriate to age;\n6. Be able to attend group session times:\n7. Have access to a private space once per week that is suitable for synchronous intervention sessions.\n\nSet B Exclusion criteria: Adolescents will be excluded if they:\n\n1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;\n2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;\n3. Have severe depression (QIDS-A-CR score \\> = 16);\n4. Have moderate or high risk for suicide (Response of \"yes\" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).\n5. Have suicide ideation (Response of \"yes\" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)\n6. Are pregnant;\n7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT;\n8. Have a sibling or other household member active in a study intervention (for this study) at the same time.","12 Years","18 Years",{"count":88,"type":21},96,[24],"In this study, we will conduct a pilot RCT of a yoga-based intervention (YBI) vs. group cognitive-behavioral therapy (gCBT) at two sites. We will recruit 48 adolescent participants each in Columbus, OH and Boston, MA (96 total). We have a priori targets for indices of feasibility and acceptability, including recruitment rate, retention for assessments, class attendance, interventionist fidelity to manuals, and participant satisfaction. We hypothesize that we will meet these metrics at both sites.",[34],[93,94,95,96],"depression","yoga","cognitive-behavioral therapy","adolescent","2026-06-08",{"date":99,"type":40},"2026-06-10",{"date":101,"type":21},"2026-06-15",{"date":103,"type":21},"2027-12",{"name":105,"class":47},"Butler Hospital",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100643688","streamlined-treatment-and-evidence-based-adolescent-counseling-and-medication-support-streams-100643688","NCT07637058","Streamlined Treatment and Evidence-based Adolescent Counseling and Medication Support (STREAMS)","STREAMS","Inclusion Criteria:\n\n* Living with HIV with confirmation by medical report and aware of their status\n* Living within a family (defined broadly, not necessarily with biological parents); - - Between the ages of 15 to 19 years\n* Prescribed ART\n* Score a 10 or greater on the PHQ-9\n\nExclusion Criteria:\n\n* an inability to understand study procedures and participant rights as assessed during informed consent\u002Fassent process with the adolescent or caregiver.","15 Years","19 Years",{"count":116,"type":21},588,[24],"Combination interventions to address mental health and adherence to HIV care in low- and middle-income countries (LMICs), are crucial to achieving the UNAIDS 95-95-95 targets as one in four adolescents living with HIV (ALWHIV) experience poor mental health and this contributes to suboptimal medication adherence and lack of viral suppression. Yet few evidence-based mental health and adherence interventions have been evaluated in sub-Saharan Africa (SSA), the region where the majority of the 1.7 million ALWHIV reside. STREAMS will determine if our streamlined combination intervention approach to mental health screening, provision of evidence-based interpersonal psychotherapy groups (IPT-G), and evidence-based family strengthening, and medication counseling is feasible and efficacious for ALWHIV in Uganda.",[34],[121,122,66,93],"HIV","Uganda","NOT_YET_RECRUITING","2026-06-04",{"date":126,"type":40},"2026-06-09",{"date":128,"type":21},"2026-12",{"date":130,"type":21},"2030-08",{"name":132,"class":47},"City University of New York, School of Public Health",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":57,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":154,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":78},"100604558","tag-team---trans-adolescent-group-therapy-100604558","NCT07151079","TAG TEAM - Trans Adolescent Group Therapy","Evaluation of Trans Adolescent Group ThErapy for Alleviating Minority Stress (TAG TEAM): a Randomised Controlled Trial","TAG TEAM","Participants will be enrolled into the RCT only if they meet all the inclusion criteria and none of the exclusion criteria.\n\nInclusion Criteria:\n\n* Identifies as trans, non-binary, or gender diverse\n* Is between the ages of 12 and 17 years inclusive\n* Has completed primary school at the time of enrolment into the study\n* Has current psychological stress symptomology as determined by a score of moderate or above on the DASS-Y\n* Provide informed consent: All participants and parent\u002Flegal guardians must be willing to give informed consent\n\nExclusion Criteria:\n\n* Has current acute suicidal symptomology as determined by a combination of clinical judgement and the results of the Ask Suicide-Screening Questions (ASQ) suicide screening tool (e.g., answer yes to question 5) to determine the risk of suicide (has an active plan and\u002For intent to suicide) at time of screening interview\n* Is actively having treatment with any other group psychological intervention at the time of enrolment into the study\n* Is not proficient in English (as the group Cognitive behaviour therapy (CBT) program will be delivered in English and funds aren't available for interpreters)\n* Previous participation in the feasibility trial\n* Is currently enrolled in tertiary study (e.g., undergraduate university)",{"count":142,"type":21},142,[24],"This project will study the effect of the TAG TEAM group CBT program on the mental health of trans and gender diverse adolescents. TAG TEAM was co-designed by researchers and clinicians with a group of trans and gender diverse young people to help trans and gender diverse adolescents understand and cope with minority stress. Minority stress includes experiences like discrimination and rejection. TAG TEAM focuses on learning and practicing skills to support mental health and wellbeing. It also includes group discussions and activities with other trans and gender diverse young people. TAG TEAM groups are run by a psychologist and a trans peer facilitator. A trans peer facilitator is a trans and gender diverse person who is there to share their experience of being trans and to support participants in the group sessions.",[146,147,148,64,34,149,150,151,152,153],"Minority Stress","Acceptability","Psychological Distress","Coping","Wellbeing","Pride","Internalised Stigma","Community Connection",[155,156,157,150,158,159],"Adolescent","Trans and gender diverse","Minority stress","Group Therapy","CBT",{"date":161,"type":40},"2026-06-05",{"date":163,"type":40},"2026-05-21",{"date":165,"type":21},"2027-03",{"name":167,"class":47},"Murdoch Childrens Research Institute",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":57,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":184,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":78},"100636769","digitally-enhanced-cognitive-behavioral-therapy-100636769","NCT07569991","Digitally Enhanced Cognitive-Behavioral Therapy","Digitally Enhanced Cognitive-Behavioral Therapy for Adolescents With Depression and Obesity","CBT+","Inclusion Criteria:\n\n* Age 12-17 years\n* Body mass index (BMI) ≥85th percentile for age and sex\n* Elevated depression symptoms, Center for Epidemiologic Studies-Depression Scale (CES-D) ≥21\n\nExclusion Criteria:\n\n* Type 2 diabetes; Fasting glucose ≥126 mg\u002FdL or HbA1c ≥6.5\n* Major developmental (e.g., intellectual developmental disability) or medical or genetic condition (e.g. cancer, Bardet-Biedhl)\n* Pregnancy\u002Fbreastfeeding (females)\n* Bariatric surgery, weight loss medication, or weight loss \\>3% in the past 3 months\n* Active suicidality or self-harm",{"count":59,"type":21},[24],"Adolescent depression is a major public health problem. Depression affects adolescents' emotional well-being now and in the future, and it also affects their physical health, especially the risk for heart disease and other cardiovascular and metabolic health problems. In adolescents with depression and obesity, evidence-based programs for depression, like cognitive-behavioral therapy (CBT), might improve physical health, in part by supporting healthy behaviors such as physical activity, nutritious eating, and getting enough sleep. Our preliminary studies provide support for this overarching hypothesis. If adolescents have access to a digital app to support practicing CBT skills in between program sessions, it might especially help them to learn skills that help to feel better and be healthier in their day-to-day lives. We are tailoring a digital app for this purpose and we will make changes to the app based on feedback from adolescents, their parents, and their doctors. Once the app is well-liked and helpful, and works well as a support for taking part in CBT, we will randomly assign 60 adolescents with depression and overweight\u002Fobesity to either \"CBT+\" - a CBT group program plus the app, or \"CBT-only\" - the CBT group program only. We will pilot test whether this research is feasible, likeable, and credible, learning information that will inform a larger study to test of CBT+ can support emotional well-being, health behavior, and cardiovascular and metabolic health in adolescents.",[34,180,181,182,183],"Obesity & Overweight","Cognitive-behavioral Therapy","Mobile Health Technology (mHealth)","Health Behavior",[95,93,185,186,187],"adolescents","cardiometabolic health","mHealth","2026-06-03",{"date":161,"type":40},{"date":191,"type":21},"2027-01-01",{"date":193,"type":21},"2028-08-01",{"name":195,"class":47},"Colorado State University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":78},"100464572","inflammatory-and-glutamatergic-mechanisms-of-sustained-threat-in-adolescents-with-depression-100464572","NCT05329441","Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression","Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression: Toward Predictors of Treatment Response and Clinical Course","TIGER","Inclusion Criteria:\n\n* All sexes and genders\n* All ethnicities\n* Ages 14-21\n* Postpubertal (Tanner stage \\> 3)\n* No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication)\n* Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram\n* The ability to provide assent, understand, and complete all study procedures\n* Caregiver consent (if applicable)\n\nExclusion Criteria:\n\n* Primary mental health diagnosis other than a depressive disorder according to DSM-V\n* Any contraindications to MRI scanning, phlebotomy, or SSRI treatment\n* Stimulant usage\n* A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes\n* Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings\n* Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure\n* Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders\n* First-degree relative with current, past, or suspected mania or psychosis","21 Years",{"count":206,"type":21},160,"Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.",[34],[93,67],"2026-05-27",{"date":212,"type":40},"2026-05-29",{"date":214,"type":40},"2023-07-06",{"date":216,"type":21},"2028-04-30",{"name":218,"class":47},"University of California, Los Angeles",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":86,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100638817","application-for-arts-based-social-prescribing-100638817","NCT07593443","Application for Arts-Based Social Prescribing","Member Engagement Application for Personalized Arts-based Social Prescriptions","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n* Aged 15-18 years enrolled in Medicaid managed care\n* Positive screen for depression and\u002For anxiety (e.g., PHQ-2 or GAD-2 ≥ 3)\n* Currently own and easily operate a smartphone\n* Have a valid e-mail address checked regularly\n* English fluency, and\n* Have a stable treatment regimen for at least 30 days prior to baseline with no planned treatment changes.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n* Endorse current suicidal ideation at study screening, defined as a response ≥ 1 (\"several days\") on Item 9 of the PHQ-9A\n* Initiate a new treatment regimen or plan on initiating a new treatment regimen (i.e., medication, psychotherapy, or mind-body interventions) at the time of enrollment.",{"count":227,"type":21},230,[24],"The goal of this clinical trial is to learn if a personalized arts-based social prescribing program, Art Pharmacy, delivered through a mobile app (SocialRx App) can improve mental health and social connectedness in adolescents aged 15-18 with depression or anxiety enrolled in Medicaid managed care.\n\nThe main question it aims to answer is:\n\nCompared to stable treatment, does participation in the Art Pharmacy program through the SocialRx App improve depression, anxiety, social connectedness, and loneliness? Researchers will compare participants receiving the Art Pharmacy program and digital companion to those receiving stable treatment (no change to existing care) to evaluate its effects on mental health and social connectedness.\n\nParticipants will:\n\nBe randomly assigned to either the Art Pharmacy program delivered through the SocialRx App or a control group receiving stable treatment.\n\nComplete online surveys at baseline and follow-up time points (e.g., 3, 6, 9, and 12 months).\n\nIf assigned to the intervention group, Art Pharmacy, participants will receive monthly arts and cultural activity recommendations, attend activities, and interact with a care navigator delivered through the SocialRx App.",[34,64,231,232],"Loneliness","Social Connectedness","2026-05-13",{"date":235,"type":40},"2026-05-18",{"date":237,"type":21},"2026-05",{"date":239,"type":21},"2028-04",{"name":241,"class":242},"SocialRx Inc","INDUSTRY",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":15,"sex":16,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100638235","co-designing-adaptations-of-a-digital-mental-health-intervention-wysa-for-adolescent-girls-with-anxiety-or-depression-in-rural-india-100638235","NCT07595029","Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India","Identifying Barriers and Enablers to Co-Design Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls in Low Resource Settings in Uttar Pradesh, India","ADOLESCENTS:\n\nInclusion Criteria:\n\n* Sex: girls\n* Marital status: Unmarried\n* Are between 13-18 years of age\n* Residing in the selected villages of Uttar Pradesh, India.\n* Have elevated anxiety and\u002For depressive symptoms on the RCADS-25.\n* Have access to a mobile phone (at least 1 mobile phone within the family).\n* Provide assent\u002F consent to participate, along with guardian consent for minors.\n\nAdolescents Exclusion Criteria:\n\n* Adolescent girls who have difficulties that would prevent them from actively participating in workshop activities (e.g. with memory or comprehension, indications of psychoses)\n* Are currently or have been in the past a girl icon in the Milaan Foundation Girl Icon program\n\nPARENTS\u002FGUARDIANS:\n\n1. Inclusion Criteria\n\n   * Are guardians or caregivers of a participating adolescent girl.\n   * Currently reside in Uttar Pradesh\n   * Provide informed consent to participate.\n2. Exclusion Criteria ● They have difficulties that would prevent them from actively participating in workshop activities (e.g. with memory or comprehension, indications of psychoses).\n\nCOMMUNITY STAKEHOLDERS \\& DECISION MAKERS\n\n1. Inclusion criteria\n\n   * Contribute to and influence local health related-decisions or services.\n   * Provide informed consent to participate.\n2. Exclusion Criteria ● Stakeholders who have difficulties that would prevent them from actively participating in workshop activities (e.g. with memory or comprehension, indications of psychoses)","13 Years",{"count":252,"type":21},179,"The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and\u002For depression in rural Uttar Pradesh, India.\n\nMore specifically, the aims of this study are to (i) explore key barriers and facilitators to adoption, engagement, and usability of a digital mental health intervention (Wysa) in this setting, and to (ii) co-design contextually appropriate app adaptations and implementation strategies in collaboration with adolescent girls, their parents\u002Fguardians, and community stakeholders. At the end of this study, we would have co-developed a roadmap of potential adaptations to Wysa with implementation strategies to iteratively test and develop during the next phases of the study.",[64,34,255],"Anxiety Disorder of Adolescence",[257,258,64,31,259,260,261,262,263,264,265,266,267,268,269,270,271],"Digital Mental Health","Adolescent Mental Health","Rural Population","India","Implementation Science","Patient Engagement","Early Intervention, Psychological","Chatbot","Low-Resource Settings","Adolescent Girls","Artificial Intelligence","Cultural Adaptation","Cognitive Behavioural Therapy","Wysa","Mental Health Access","2026-05-12",{"date":274,"type":40},"2026-05-19",{"date":237,"type":21},{"date":277,"type":21},"2026-11",{"name":270,"class":242},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":78},"100526831","better-sleep-study-100526831","NCT06139861","Better Sleep Study","A Confirmatory Efficacy Trial of Engaging a Novel Sleep\u002FCircadian Rhythm Target as Treatment for Depression in Adolescents","Inclusion Criteria:\n\nExclusion Criteria:\n\n* mental health\u002Fbehavioral symptoms that would preclude productive engagement in study assessments or intervention (e.g., active psychosis; Bipolar Disorder; drug dependence\n* severe or unstable medical or psychiatric condition such that treatment has changed within the last month or is expected to change during the course of the study or that would preclude ability to adhere to study procedures (e.g. terminal end-stage cancer)\n* current use of medications or herbs with known effects on sleep\n* plan to undergo or have had medication change in the last 8 weeks",{"count":287,"type":21},200,[24],"The overall aim of this proposal is a confirmatory efficacy trial sufficiently powered and designed to test the hypothesis that improving the relationship between biological circadian timing and waketime, a novel modifiable target, improves depression outcomes in a subgroup of adolescents with depression and a misaligned relationship between biological circadian timing and waketime utilizing a cognitive-behavioral sleep intervention.",[34,291],"Delayed Sleep Phase",[31,293,294,295],"Adolescents","Sleep","Intervention","2026-05-07",{"date":298,"type":40},"2026-05-11",{"date":300,"type":40},"2024-03-15",{"date":193,"type":21},{"name":303,"class":47},"Children's Hospital Los Angeles",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":250,"maxAge":86,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":48},"100486701","mindfulness-based-fmri-neurofeedback-for-depression-100486701","NCT05617495","Mindfulness-Based fMRI Neurofeedback for Depression","Targeting Adolescent Depression Symptoms Using Network-based Real-time fMRI Neurofeedback and Mindfulness Meditation (NIMH); Mindfulness-Based Real-Time fMRI Neurofeedback for Depression (IRB)","mbNF","Inclusion Criteria:\n\n* Ages 13-18 years-old\n* Written informed assent\u002Fconsent and parental\u002Fguardian permission for 13-17 year-olds or informed consent for 18 year-olds\n* Tanner puberty stage ≥3\n* Meets current diagnostic criteria for MDD\n* English fluency\n\nExclusion Criteria:\n\n* Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders\n* Substance use disorder, moderate or severe in past 6 months\n* Active suicidal ideation with a specific plan\n* History of seizure disorder\n* Medical or neurological illness (e.g., severe head injury)\n* MRI contraindications\n* Current psychotropic medication use other than antidepressant medication\n* Intelligence quotient (IQ) \\\u003C80.",{"count":313,"type":21},90,[24],"In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promising treatment target, as it is well-characterized at the neural level and contributes to depression onset, maintenance, and recurrence as well as predicts treatment non-response. Accordingly, the proposed research will investigate whether an innovative mindfulness-based real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention successfully elicits change in the brain circuit underlying rumination to improve clinical outcomes among depressed adolescents.",[34,317],"Rumination",[319,320,317,27],"Real-time fMRI Neurofeedback","Mindfulness","2026-04-24",{"date":323,"type":40},"2026-04-29",{"date":325,"type":40},"2024-04-10",{"date":44,"type":21},{"name":328,"class":47},"Columbia University",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":18,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":78},"100628043","fluoxetine-and-understanding-social-experiences-100628043","NCT07456501","Fluoxetine and Understanding Social Experiences","Investigating the Effects of Fluoxetine on Reinforcement Learning and Social Cognition in Healthy Young People","FUSE","Inclusion Criteria:\n\n* Be aged 18-24 years (inclusive)\n* Be resident in the UK for the duration of the study\n* Have normal or corrected to normal vision\n* Participant is willing and able to give informed consent for participation in the research\n* Sufficiently fluent English to understand and complete the study\n\nExclusion Criteria:\n\nPsychiatric History:\n\n* Current or past diagnosis of any psychiatric disorder, as determined by the SCID-5 and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;\n* First degree relative with a diagnosis of mania.\n\nLifestyle:\n\n* Heavy smoker or vaper (\\> 10 cigarettes per day, or \\>2 mL e-liquid, or \\>15mg\u002Fday from a nicotine patch);\n* Heavy use of caffeine (drink \\> 4 of 250ml cups\u002Fcans of coffee or energy drinks per day);\n* Heavy alcohol drinker (drink \\>14 standard alcoholic drinks per week);\n* Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances.\n* Unable or unwilling to consume gelatine (study capsules will be gelatine-based).\n\nPhysical Health:\n\n* Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;\n* Known contraindication to fluoxetine, such as hypersensitivity to fluoxetine or any component in its formulation;\n* Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;\n* Breastfeeding.\n\nMedical History:\n\n* Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study. This can include but is not limited to: seizures or epilepsy, abnormal heart rhythm, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);\n* Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury);\n* Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor. This can include but is not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm.\n\nPrior Study Participation:\n\n* Participation in any other psychological or medical experiment involving taking any kind of drug\u002Fmedication\u002Fvaccine, within the last 3 months;\n* Participation in any other study involving the current or similar tasks, within the last 6 months.\n\nOther considerations:\n\n•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator\u002Fmedical advisor, may influence the scientific integrity of the study, or the participant's safety or ability to participate in the study.",{"count":338,"type":21},80,[24],"Adolescence is a critical developmental period marked by significant social, cognitive, and emotional changes. Unfortunately, it is also a time when the risk of depression and anxiety rises dramatically. Early, effective treatment is essential to mitigate long-term impacts on relationships, education, and life satisfaction. While psychological therapies are recommended as first-line treatment for mild to moderate depression in young people, antidepressant use (particularly SSRIs such as Prozac) has risen sharply, especially among girls aged 15-17.\n\nDespite their widespread use, there is limited research on how SSRIs address adolescent depression, leaving clinicians with little evidence to guide treatment decisions. The Fluoxetine and Understanding Social Experiences (FUSE) study aims to shed light on how Prozac (medically known as fluoxetine) influences decision-making in healthy young people in four key areas that are known to be affected by depression: emotional processing (e.g., facial expression recognition), social function (e.g., sensitivity to peer rejection), reward processing (e.g., how people learn from rewards and punishments), and motivation (e.g., how people make decisions about whether a certain outcome or reward is worth the effort to obtain). Some of the tests employed in the study use facial expression and heart-rate recording as aditional measures. We are aiming to recruit and test 80 young people between the ages of 18 and 24.\n\nWhen included in the study, participants are randomly assigned to receive either a weeklong treatment with fluoxetine, or a placebo (a pill with no active ingredients). The study follows a double-blind design, which means that neither the researchers nor the participants are aware of the treatment received so as to not influence the results.\n\nWe belive that fluoxetine will have beneficial effects on social decision-making in young people, which might manifest as increased accuracy labelling positive facial expressions, less sensitivity to negative feedback, lower self-reported negative mood in response to social exclusion and reduced heart rate\u002Fnegative facial expressivity in response to unpleasant social experiences.\n\nThe FUSE study aims to deepen our understanding of how antidepressants affect decision-making in young people, at a time when antidepressant prescriptions have risen but research is scarce. By identifying the exact domains of functioning which are affected by antidepressant use in this age group, this research will help inform which young people are likely to benefit most from drug treatment.\n\nThe project results will be published in peer-reviewed journals and presented at academic conferences. We are also working with a group of young advisors who will help us decide how to best share our results with others in their age group. A brief summary of the study findings will also be provided to participants who would like to receive it. All research data, excluding information that could identify participants, will be stored safely for at least 10 years after final publication or public release.",[34,342,343],"Antidepressant Activity in Healthy Volunteers","Healthy Adult Participants",[31,345,346,347,348,349,350,351,352],"Adolescent depression","Fluoxetine","Prozac","Young people","Reward processing","Effort-based decision-making","Social cognition","Peer rejection","2026-03-02",{"date":355,"type":40},"2026-03-06",{"date":357,"type":21},"2026-03",{"date":359,"type":21},"2027-07-22",{"name":361,"class":47},"University of Oxford",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":78},"100612785","innov5-mh-maroc-integrated-mental-health-care-for-adolescents-and-adults-in-primary-care-centers-and-schools-in-morocco-100612785","NCT07258095","INNOV5-MH-MAROC: Integrated Mental Health Care for Adolescents and Adults in Primary Care Centers and Schools in Morocco","INNOV5-MH-MAROC: Multicenter Pragmatic Randomized Controlled Trial Evaluating an Integrated Program of Five WHO Innovations in Mental Health in Morocco","INNOV5-MH","Inclusion Criteria:\n\n* Adolescents (12-17 years) and adults (≥18 years) attending participating primary care centres or high schools in Morocco.\n* Clinically significant depressive and\u002For anxiety symptoms identified by screening (PHQ-9 and\u002For GAD-7) according to study thresholds.\n* Able to understand study procedures and provide informed consent (or parental consent and adolescent assent for minors).\n* Planning to remain in the study area for at least 12 months.\n\nExclusion Criteria:\n\n* Acute psychiatric emergency requiring immediate specialised care (e.g. psychosis, high-risk suicidal crisis, severe substance use disorder).\n* Cognitive impairment or severe medical condition preventing participation in the intervention or assessments.\n* Current participation in another interventional mental health trial.\n* Any other situation judged by the investigator to make participation unsafe or inappropriate.",{"count":371,"type":21},146,[24],"Depression and anxiety are highly prevalent among adolescents and adults in Morocco, while access to evidence-based care in primary care centers and schools remains limited. This multicenter pragmatic randomized controlled trial evaluates an integrated mental health program inspired by WHO priorities. The INNOV5 intervention combines: (1) a collaborative care model in primary care; (2) mhGAP-based task-shifting and stepped care; (3) validated digital mental health interventions; (4) virtual reality exposure therapy for selected anxiety- or trauma-related cases; and (5) a school-based mental health promotion component in participating high schools. The primary objective is to compare the change in depressive symptoms (PHQ-9) at 6 months between INNOV5 and enhanced treatment as usual (TAU+). Secondary objectives include effects on anxiety (GAD-7), quality of life (WHOQOL-BREF), suicidal ideation and behavior (C-SSRS), functioning, school attendance, and feasibility and acceptability of the program.",[34,375,64,376],"Depression in Adults","Mental and Behavioural Disorders",[31,64,378,379,380,381,382,383,384,385],"Adolescent mental health","Primary care","School-based mental health","Digital mental health","Virtual reality exposure","mhGAP","Task-shifting","Morocco","2025-11-20",{"date":388,"type":40},"2025-12-02",{"date":390,"type":21},"2028-03-01",{"date":392,"type":21},"2029-12-31",{"name":394,"class":47},"Swiss Medical Academy Maroc",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":86,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":78},"100492384","mechanisms-of-depression-and-anhedonia-in-adolescents-linking-sleep-to-reward--and-stress-related-brain-function-100492384","NCT05691439","Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function","Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep Duration and Timing to Reward- and Stress-Related Brain Function","MoDA","Inclusion Criteria:\n\n1. 14-18 years of age\n2. Currently in high school\n3. short and late sleep (weekday sleep duration ≤ 7 h and bedtime ≥ 22:30 (10:30 pm); n=100) or long and early sleep (weekday sleep duration \\> 7 hours and bedtime ≤ 22:30 (10:30 pm); n=50), indexed by the Munich Chronotype Questionnaire\n4. Lifetime stressful event frequency ≥ 2 on the Stress and Adversity Inventory (STRAIN) Screener\n5. Depressive symptom severity t-score greater than or equal to 45 on the Patient Reported Outcomes (PROMIS) Depression scale\n6. English language fluency\n\nExclusion Criteria:\n\n1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for current moderate to severe alcohol\u002Fsubstance use disorder (≥4 symptoms);\n2. Current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia;\n3. Lifetime diagnosis of bipolar or schizophrenia spectrum disorder;\n4. Certain medical conditions (e.g., serious neurological disorder, heart failure or serious heart trouble, history of head injury with unconsciousness \\> 5 minutes);\n5. Conditions that are contraindicated for magnetic resonance imaging (MRI; e.g., ferrous metal in the body);\n6. Positive screen for participant-reported eye disease, epilepsy, or photosensitizing medications that are contraindicated during the manipulation condition when bright light is administered (e.g., psychiatric neuroleptic drugs \\[e.g., phenothiazine\\], psoralen drugs, antiarrhythmic drugs \\[e.g., amiodarone\\], antimalarial and antirheumatic drugs, porphyrin drugs used in photodynamic treatment of skin diseases);\n7. Use of melatonin if participant is not willing to discontinue use for the duration of the study.\n\nWe will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events:\n\n1. urgent suicide risk, defined by moderate\u002Fsevere risk per Columbia Suicide Severity Rating Scale (CSSRS) and clinician determination that current risk requires immediate action;\n2. travel across two or more time zones within the month prior to the overnight study visits;\n3. beginning or ending a prescribed medication within 2 months of the observational study;\n4. prescribed medication dose changes within the timeframe calculated as 5x the drug's half-life \\[the time to reach pharmacokinetic steady-state\\] before the initiation of the observational or experimental studies;\n5. anticipated change in prescribed medications or medication dosing during the observational or experimental studies;\n6. current symptoms of airborne infectious illness prior to laboratory visits.\n\nParticipants with positive breathalyzer screen (blood alcohol level \\> .02) will be rescheduled for an alternative overnight visit date.",{"count":404,"type":21},150,[24],"This research will use biobehavioral approaches to generate understanding about the linkages between sleep duration and timing, stressful life events, and depressive symptoms in adolescents, with a long-term aim of developing effective preventative interventions.",[34],"2025-11-13",{"date":410,"type":40},"2025-11-17",{"date":412,"type":40},"2023-03-27",{"date":414,"type":21},"2026-12-31",{"name":416,"class":47},"University of Oregon",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":56,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":440},"100603603","promoting-mental-health-among-at-risk-adolescents-in-malaysia-100603603","NCT07138664","Promoting Mental Health Among At-risk Adolescents in Malaysia","MyHeRo","Inclusion Criteria:\n\n1. Adolescent (aged 12-14) who are in the first two years (Form 1 and Form 2, equivalent to year 7 and 8 in the United Kingdom school system, respectively) in lower secondary schools.\n2. Adolescents score moderate to severe levels of anxiety and\u002For depression on the Depression Anxiety and Stress Scale-21 (DASS-21) based on the original cut-off norms (DASS-21 Anxiety scale ≥ 10 and\u002For DASS-21 Depression scale ≥ 14).\n3. Adolescent's parent\u002Fcarer provides written consent.\n\nExclusion Criteria:\n\n(1) Being diagnosed with neurodevelopmental disorders. (2) Being diagnosed with intellectual disability.\n\n\\-",{"count":425,"type":21},428,[24],"The primary objective of this trial is to evaluate a school-based intervention designed to promote mental health among at-risk adolescents from low-income communities in Malaysia. The study will employ a two-arm, cluster randomised controlled trial design, comparing a school-based intervention to a control condition. Adolescents will be recruited from at least 20 secondary schools located in economically disadvantaged rural and urban areas of Malaysia. Assessments will take place at multiple time points: during screening, at baseline (pre-intervention), immediately after the intervention (8 weeks), and at two follow-up points-6 and 12 months post-intervention. The primary outcomes are a reduction in anxiety and depressive symptoms, along with improved mental wellbeing at the 12-month follow-up.",[34,64],[64,31,293,430],"School-based intervention","2025-08-16",{"date":433,"type":40},"2025-08-24",{"date":435,"type":21},"2025-08",{"date":437,"type":21},"2026-09",{"name":439,"class":47},"University of Roehampton",5,{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":78},"100494023","neuro-affective-response-to-light-in-depressed-adolescents-and-young-adults-100494023","NCT05712772","Neuro-affective Response to Light in Depressed Adolescents and Young Adults","Inclusion Criteria:\n\n* Elevated Depressive Symptoms \\[PHQ9≥5 And (Item 1≥1 or Item 2≥1)\\]\n* (If \\\u003C18yr) Parent or guardian can attend the baseline clinical interview\n\nExclusion Criteria:\n\n* Unable to read and write in English\n* Intellectual disability.\n* Left or mixed handedness\n* Changes to psychotropic medication type or dosage in the past 2 months\n* Lifetime bipolar disorder or schizophrenia, or substance\u002Falcohol disorder in the past 3 months.\n* Factors influencing light and color sensitivity (i.e., color-blindness, serious ophthalmological conditions, photo-sensitizing medication).\n* Factors influencing the ability to maintain a stable sleep schedule (i.e., shift work, severe sleep disorders, extremely late or early sleep schedule).\n* Severe medical illness, neurological disorders, or history of head trauma.\n* Current pregnancy or nursing\n* MRI contraindication (e.g., metals in the body, recent tattoo, claustrophobia)\n* Positive alcohol or substance use screen at MRI visit","30 Years",{"count":338,"type":21},[24],"The goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. The main questions this study aims to answer are:\n\n* Does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals?\n* Are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than young adults?\n\nParticipants will complete:\n\n* A magnetic resonance imaging brain scan, in which we will examine the effect of blue versus red light on emotional brain function at rest and in response to rewards and losses.\n* A pupillometry test of sensitivity to blue vs red light\n* Clinical interviews and surveys\n* Screening measures for drug and alcohol use, MRI safety, and current pregnancy \\[if relevant\\]\n* Home sleep tracking with sleep diary and actigraphy for one week",[34,375],"2025-08-05",{"date":454,"type":40},"2025-08-11",{"date":456,"type":40},"2023-06-14",{"date":458,"type":21},"2026-07-31",{"name":460,"class":47},"University of Pittsburgh",{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":476,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":78},"100537143","telehealth-behavioral-activation-for-teens-100537143","NCT06273995","Telehealth Behavioral Activation for Teens","Inclusion Criteria:\n\n1. Participants must be enrolled in the Texas Youth Depression Suicide Research Network (TX-YDSRN) Registry Study;\n2. Be between the ages of 12- 18 or currently enrolled in high school;\n3. Have a caregiver that is willing to participate in the program;\n4. Be able to commit to weekly sessions for eight weeks;\n5. Be currently experiencing depressive symptoms;\n6. Be able to participate in telehealth services within the state of Texas;\n7. Be willing to provide consent\u002Fassent (parents\u002Flegally authorized representative (LAR)\u002Fguardian or young adult participant, aged 18 or older, must be willing to provide consent; youth, aged 12-17, must be willing to provide assent);\n8. Be able to read, write and speak English or Spanish sufficiently to understand the study procedures and provide written informed consent to participate in the study;\n9. Be willing to dedicate appropriate time to complete scheduled study assessment and measures and attend intervention sessions (both parent\u002FLAR\u002Fguardian and youth)\n10. Be able to provide a reliable means of contact.\n\nExclusion Criteria:\n\n1. Have an acute medical or psychological condition(s) that that would, in the judgment of the study medical clinician, make participation difficult or unsafe;\n2. Have an acute medical or psychological condition(s) that would result in an inability to accurately complete study requirements (e.g., neurological conditions or significant neurodevelopmental concerns);\n3. Have active psychotic or manic symptoms resulting in altered mental status and inability to provide assent or requiring immediate attention and\u002For higher level of intervention;\n4. Have a parent\u002FLAR\u002Fguardian who is deemed cognitively unable to provide consent (if youth participant, aged 12-17).",{"count":468,"type":21},250,[24],"Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depressed youth. Additionally, it has been shown as a promising intervention that can be conducted in a brief, virtual format and can be effectively implemented by both trained clinicians and trained, non-licensed interventionists. This project will provide Behavioral Activation for youth (12-17) experiencing depression or suicidal ideation who are currently enrolled in the Youth Depression Suicide Network study in Texas.",[31,472,34,473,474,475],"Suicide and Self-harm","Depression Mild","Depression Moderate","Depression Severe",[477,93,185],"behavioral activation","2025-07-18",{"date":480,"type":40},"2025-07-20",{"date":482,"type":40},"2024-03-01",{"date":484,"type":21},"2029-12-01",{"name":486,"class":47},"Baylor College of Medicine",{"id":488,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":489,"targetDuration":4,"studyType":22,"phases":490,"briefSummary":25,"conditions":491,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":496,"leadSponsor":497,"locationsCount":48},"100472876",{"count":20,"type":21},[24],[27,28,29,30,31,32,33,34,35],"2025-07-08",{"date":494,"type":40},"2025-07-11",{"date":42,"type":40},{"date":44,"type":21},{"name":46,"class":47},{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":114,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":78},"100556310","accelerated-intermittent-theta-burst-in-treatment-naive-adolescents-100556310","NCT06523439","Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents","Investigating a Truncated Version of SAINT in Treatment-Naive Adolescents With Depression: An Open-Label Acceptability Trial","SAINT-KID","Inclusion Criteria:\n\n1. Male or Female, between the ages of 14 and 19 at the time of screening.\n2. Able to read, understand, and provide written, dated assent and\u002For consent prior to screening. Proficiency in English sufficient to complete questionnaires and follow instructions during aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.\n3. Diagnosed with Major Depressive Disorder (MDD) with a current Major Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).\n4. No prior major depressive episodes (MDEs) as determined by MINI-KID\n5. HAMD-17 score of ≥20 at screening (Visit 1).\n6. Treatment-naive as determined by the ATHF (no adequate antidepressant trials prior to screening defined as fewer than 4 weeks of antidepressant medication and fewer than 8 psychotherapy sessions in lifetime; willingness to taper medications and stop psychotherapy if recently started and within the window defined above.)\n7. TMS naive.\n8. Access to ongoing psychiatric care before and after completion of the study.\n9. In good general health, as evidenced by medical history.\n10. Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. High-risk for suicide or active suicidal ideation (Suicidal Ideation Questionnaire- Junior \\[SIQ-JR\\] ≥ 31).\n3. The presence or diagnosis of prominent anxiety disorder, or dysthymia (\\>3 on SAPAS; \\>10 on GAD-7)\n4. Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)\n5. Current mania or psychosis\n6. Bipolar Affective Disorder and\u002For primary psychotic disorders.\n7. Autism Spectrum disorder or Intellectual Disability\n8. A diagnosis of obsessive-compulsive disorder (OCD)\n9. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.\n10. Urine screening test positive for illicit substances.\n11. Any history of ECT (greater than 8 sessions) without meeting responder criteria\n12. Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).\n13. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure\u002Fepilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.\n14. Untreated or insufficiently treated endocrine disorder.\n15. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)\n16. Contraindications to MRI (ferromagnetic metal in their body).\n17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.\n18. Depth-adjusted aiTBS treatment dose \\> 65% maximum stimulator output (MSO)\n19. Treatment with another investigational drug or other intervention within the study period.\n20. Any other condition deemed by the PI to interfere with the study or increase risk to the participant.",{"count":507,"type":21},40,[24],"This is a single-site open-label clinical trial of the Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) protocol. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS) and specifically as SAINT®-is effective as a first-line therapy in treating adolescents aged 14-19 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial.\n\nThe main questions this trial aims to answer are:\n\n* Does SAINT® relieve symptoms of depression as a first-line therapy in adolescents?\n* Is SAINT® a feasible option as a first-line treatment for adolescent depression?\n\nResearchers will measure the depression symptoms in adolescent participants before and after SAINT®. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment.\n\nAdolescent participants will:\n\n* Remain antidepressant-free throughout the study period of 6-7 weeks.\n* Receive an MRI of their head for precision targeting\n* Receive 5 days of aiTBS (SAINT®)",[27,34,31,511],"Major Depressive Episode",[513,514,515,516,517,518,519],"Stanford Accelerated Intelligent Neuromodulation Therapy","SAINT","Transcranial Magnetic Stimulation","Accelerated Theta Burst Stimulation","Accelerated Intermittent Theta Burst Stimulation","TMS","TMS in Adolescents","2024-12-06",{"date":522,"type":40},"2024-12-12",{"date":524,"type":21},"2025-01",{"date":437,"type":21},{"name":527,"class":47},"University of Texas at Austin",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":15,"sex":16,"minAge":250,"maxAge":57,"enrollmentInfo":534,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":78},"100564770","evaluating-the-role-of-the-microbiome-in-antidepressant-treatment-in-adolescents-100564770","NCT06633497","Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.","Inclusion Criteria:\n\n* Subjects from all ethnic backgrounds will be eligible to participate.\n* Having clinically significant depressive symptoms based on a score \\>40 on the Children's Depression Rating Scale-Revised\n* Prescribed more than 5mg of Fluoxetine (Prozac)\n* Has an identifiable legal guardian.\n\nExclusion Criteria:\n\n* Has been taking a standing psychotropic medication in the past 6 months\n* Has been taking antibiotics or metformin during the past 6 months (known strong effects on gut microbiome)\n* Admitted to RCHSD CAPS post-overdose (potential strong effects on gut microbiome)\n* Currently using nicotine-containing substances (known strong effects on gut microbiome)",{"count":535,"type":21},100,"The goal of this observational study is to learn about the role of the human gut microbiome in antidepressant treatment response in adolescents with Major Depressive Disorder (MDD). Specifically, the study aims to collect microbiota samples of adolescents treated with fluoxetine, over the span of 8-weeks, to:\n\n* determine the influence of the microbiome on the efficacy of fluoxetine to treat adolescent depression.\n* test whether the gut microbiome from different timepoints can predict ultimate success of fluoxetine\n* investigate the interaction of gut microbiome composition and pharmacogenetic metabolizer status on steady-state plasma concentrations of fluoxetine.\n\nDepression symptom severity will be evaluated upon enrollment and 6-weeks into antidepressant treatment.",[34],"2024-10-31",{"date":540,"type":40},"2024-11-04",{"date":542,"type":21},"2024-11",{"date":544,"type":21},"2026-10",{"name":546,"class":47},"University of California, San Diego",{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":555,"conditions":556,"keywords":559,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":78},"100567476","evaluation-of-the-naturalistic-user-experience-of-the-website-ich-bin-alles-schule-i-am-everything-school-100567476","NCT06668688","Evaluation of the Naturalistic User Experience of the Website \"ich Bin Alles @Schule\" (i Am Everything @school)","Evaluation of the Naturalistic User Experience of the Website \"ich Bin Alles @Schule\" (i Am Everything @school) - an Information Platform for Educational Professionals on Depression and Mental Health in Childhood and Adolescence","Inclusion Criteria:\n\n* 40 seconds Website-use\n\nExclusion Criteria:\n\n\\-",{"count":535,"type":21},"The aim of this study is to investigate the naturalistic user experience and acceptance of the German website \"ich bin alles @Schule\". This website for educational professionals offers information on depression and mental health of pupils. Another aim of this study is to determine whether the desired target groups of the website can be reached.",[31,557,558,34],"Depressive Disorder","Depression in Children",[93,560,561,185,66,562,563,564,565],"prevention","web-based","school","user experience","acceptance","teachers","2024-10-30",{"date":538,"type":40},{"date":569,"type":40},"2024-07-05",{"date":571,"type":21},"2025-07",{"name":573,"class":47},"Ludwig-Maximilians - University of Munich",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":78},"100567477","evaluation-of-the-naturalistic-user-experience-of-the-website-ich-bin-alles-100567477","NCT06668701","Evaluation of the Naturalistic User Experience of the Website \"ich Bin Alles\"","Evaluation of the Naturalistic User Experience of the Website \"ich Bin Alles\" - an Information Platform for Children and Adolescents with and Without Depression and Their Relatives","Inclusion Criteria:\n\n* 40 seconds website-use\n\nExclusion Criteria:\n\n* no exclusion criteria",{"count":582,"type":21},300,"Using a multi-method approach, the aim of this study is to investigate the naturalistic user experience and acceptance of the German website \"ich bin alles\". This website offers evidence-based information about the symptoms, causes, course, treatment, and prevention of youth depression. Another aim of this study is to determine whether the desired target groups of the website can be reached.",[557,31,558,34],[93,560,561,185,586,563,564],"depression literacy",{"date":538,"type":40},{"date":589,"type":40},"2024-06-20",{"date":591,"type":21},"2025-06",{"name":573,"class":47}]